⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CABA News
Cabaletta Bio, Inc. Common Stock
CD19 Inhibitors Market to Witness Significant Expansion During the Forecast Period (2025-2034) as Autoimmune and Oncology Pipelines Accelerate | DelveInsight
prnewswire.com
GILD
INCY
BIIB
NVS
AMGN
JNJ
ABBV
BMY
AZN
MRK
PFE
TGTX
XNCR
CABA
IMUX
ZNTL
GLPG
CLNN
AUTL
Cabaletta Bio to Participate in the TD Cowen 46th Annual Health Care Conference
globenewswire.com
CABA
Cabaletta Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
globenewswire.com
CABA
Cabaletta Bio Announces 2026 Strategic Priorities
globenewswire.com
CABA
Cabaletta Bio Reports Third Quarter 2025 Financial Results and Provides Business Update
globenewswire.com
CABA
Cabaletta Bio to Participate in Upcoming Investor Conferences in November and December
globenewswire.com
CABA
Cabaletta Bio Presents Positive Clinical Data and Development Updates for Rese-cel at ACR Convergence 2025
globenewswire.com
CABA
Cabaletta Bio Announces Appointment of Steve Gavel as Chief Commercial Officer and Award of Inducement Grant
globenewswire.com
CABA
Cabaletta Bio Presents First Rese-cel Data with No Preconditioning Demonstrating Biologic Activity and Early Clinical Responses at the 2025 ESGCT Annual Congress
globenewswire.com
CABA